DVM, MSc, PhD, MRCVS
Dr. O'Callaghan received his Doctorate in Veterinary Medicine and MSc and PhD degrees in Epidemiology from the University of Guelph, based on work conducted on the epidemiology of infections of livestock while a Medical Research Council of Canada Fellow at the International Livestock Research Institute in Nairobi, Kenya. He continued his research and training in infectious diseases epidemiology as a Wellcome Trust Senior Research Fellow at the University of Warwick. In 2001 he joined the NCIC Clinical Trials Group where he continues to oversee the Gastrointestinal and Brain Site Committees as Senior Investigator. He is also a Professor in the Department of Public Health Sciences. His research interests are diverse and include clinical trials design and methodology and infectious disease epidemiology.
Dr. Booth studied medicine at Queen's University before undertaking further training in internal medicine and medical oncology at the University of Toronto. He completed a research fellowship at the National Cancer Institute of Canada Clinical Trials Group and started a full-time faculty appointment within the Division of Cancer Care and Epidemiology at the Queen's Cancer Research Institute in July 2008.His clinical interests involve gastrointestinal and genitourinary cancer. He has an active research program in population-based cancer outcomes and clinical trial methodology. Specifically, he evaluates how the findings of landmark randomized controlled trials are translated into the general population and whether the societal benefits of therapy are what one might expect based on the clinical trial results.
MB, BCh, FRACP, MD
Penny Bradbury is a medical oncologist; Assistant Professor within the Department of Oncology at Queen’s University and holds a Cancer Care Ontario Research Chair in Experimental Therapeutics. She is a graduate of Cardiff University Medical School, UK. She undertook specialist medical oncology training at the MidCentral Regional Cancer Treatment Service in New Zealand, and at the Cancer Research UK Medical Oncology Department, Churchill Hospital, Oxford, UK, obtaining the FRACP in 2005. She undertook fellowship training in Thoracic Oncology at Princess Margaret Hospital, Toronto, and a one year Drug Development Fellowship with the NCIC Clinical Trials Group, as part of The Terry Fox Foundation Training Program in Transdisciplinary Cancer Research at Canadian Institutes of Health Research. She has a research interest in the evaluation of new therapies for the management of thoracic malignancies and clinical trial methodology. Within the NCIC CTG, she is the physician coordinator for the lung disease site and for National and International thoracic malignancy clinical trials.
Group Administrator, NCIC Clinical Trials Group
Alison Urton is the Group Administrator at the NCIC Clinical Trials Group and has been with the group since 2003. As the Group Administrator, Alison is responsible for providing administrative leadership and direction for the Group’s operations, both internally at Queen’s University and in the broader national and international clinical trials communities. Alison facilitates the development and implementation of the of the Group’s strategic direction as a key resource for the Director. This includes aligning compliance and trial conduct aspects with applicable regulations, guidelines, and standard operating procedures.
MSc, MD F.R.C.P(C)
Dr. Michael Brundage is a professor of oncology and of community health and epidemiology at Queen’s University and is the Head of the Radiation Treatment Program at the Cancer Centre of Southeastern Ontario at Kingston General Hospital. He has a busy clinical practice, a post-graduate teaching portfolio, and research programs in medical decision-making, the design and analysis of clinical trials, and the use of quality of life outcome assessments. He trained in Radiation Oncology at Princess Margaret Hospital, and completed an M.Sc. in Community Health and Epidemiology at Queen’s University. Brundage joined the Department of Oncology at Queen’s in 1991 and became a founding member of the staff of the Radiation Oncology Research Unit (1992), now a division of the Queen’s Cancer Research Institute. Brundage co-directs the clinical decision making group of Research Unit and is co-chair of the Quality of Life Committee of NCIC Clinical Trials Group. He has over 200 published papers and abstracts in the peer-reviewed literature.
Bingshu Chen joined the NCIC Clinical Trials Group as senior biostatistician and assistant professor in the Department of Community Health and Epidemiology, Queen's University in July 2008. Dr. Chen completed his Ph. D. in biostatistics at the University of Waterloo, then spent four years at the United States National Cancer Institute in the Biostatistics Branch, Division of Cancer Epidemiology and Genetics, first as a Postdoctoral Fellow and then as a Research Fellow. He was an Assistant Professor in the Department of Mathematics and Statistics at Concordia University from 2007 to 2008. His research interests are survival analysis, statistics computation, design and analysis of clinical trials and cancer epidemiology
Dr. Kim N. Chi is a medical oncologist at the Vancouver Cancer Centre, BC Cancer Agency and the Prostate Centre at Vancouver Hospital, and an Associate Professor of Medicine with the University of British Columbia with a research focus on novel therapeutics and genitourinary cancers. He is an experienced investigator on the design and conduct of clinical trials and holds peer reviewed grant funding from the U.S. Department of Defense, the Canadian Cancer Society/National Cancer Institute of Canada (NCIC), the Canadian Institutes of Health Research, the Terry Fox Research Institute and the Prostate Cancer Research Foundation. He has collaborated with investigator cooperative groups nationally and internationally as well as with industry partners from small biotechnology start-ups to large pharmaceutical companies for the investigation of novel agents from the pre-clinical stage to registration phase III studies. At the BC Cancer Agency, he currently is the Medical Director for the Clinical Trials Unit and chairs the provincial Genitourinary Cancer Systemic Therapy Group. For the NCIC-Clinical Trials Group, he serves on the executive committee of the Genitourinary Disease Site, chairs the Advanced Prostate Cancer Disease Oriented Group and chair for the Investigational New Drug Program. He is also a member of the US NCI CTEP Prostate Cancer Task Force Committee.
B.Sc, MD, FRCP(C)
Dr. Janet Dancey is Director, Clinical Translational Research NCIC Clinical Trials, Program Leader, High Impact Clinical Trials, Ontario Institute for Cancer Research; Chair, Experimental Therapeutics Network, Cancer Care Ontario; and Professor, Department of Oncology, Queen's University.
Among her duties are to coordinate translational research activities for the NCIC CTG and to foster and support translation research in clinical trials across the province of Ontario. Among her National and International activities, Chair, Biomarker Task Force for the Investigational Drug Steering Committee, Cancer Therapy Evaluation Program (CTEP), US National Cancer Institute (US-NCI) and Member of the US-NCI Program for the Assessment of Clinical Cancer Tests. Prior to joining the NCIC CTG, Dr. Dancey was Associate Chief, Investigational Drug Branch, CTEP, US-NCI where she coordinated the development of over 200 phase 1-3 trials of experimental therapeutics, including trials of novel targeted agent combinations and biomarker studies. Dr. Dancey received her MD (Magna cum Laude) from the University of Ottawa and completed her residency training in internal medicine and medical oncology at the University of Toronto. In 1994-95, she was a research fellow with the NCIC CTG and continued her fellowship training at the Institut Gustave Roussy in France. Dr. Dancey has special expertise in new anti-cancer drug development, linking drug and biomarker development, and associated clinical trials methodology. She is the author of co-author of over 100 publications in peer-review journals, 100 abstracts presented at scientific meetings and 15 book chapters. She has been an invited speaker at numerous local, national and international meetings, and has been Chair for development therapeutics and biomarker sessions for ASCO and AACR Annual Meetings, and EORTC-NCI-AACR Molecular Targets Meetings.
Bernie Eigl is a medical oncologist at the Tom Baker Cancer Centre (TBCC) in Calgary, AB. He is the medical director of the TBCC clinical research unit, and the acting director of the Alberta Clinical Cancer Research Unit (ACCRU). His research interests are in genitourinary and early phase clinical research as well as health services research.
Elizabeth Eisenhauer is Director of the NCIC Clinical Trials Group Investigational New Drug Program based at Queen’s University in Kingston ON Canada. She also holds an appointment as a Professor in the Department of Oncology at Queen’s. She obtained her MD at Queen’s and went on to train in Internal Medicine and Hematology, obtaining fellowships from the Royal College of Physicians and Surgeons (Canada) in 1980 and 1981.
Her main research interest and activity is the coordination of phase I and II trials of a wide range of novel anticancer agents through the NCIC CTG network of investigators. She has served on numerous national and international committees in the area of oncology research.
In 1998 she was the Michel Clavel Award lecturer at the NCI-EORTC Symposium on New Drugs in Cancer Treatment held in Amsterdam. In 2002 she was awarded the O. Harold Warwick Prize by the National Cancer Institute of Canada that recognizes a scientist whose research has had a major impact in Cancer Control in Canada. In 2010 The Society of Gynecologic Oncology of Canada (GOC) presented Dr. Eisenhauer with the GOC Presidential Medal Award in recognition of her outstanding contributions to gynecologic oncology in Canada and Abroad.
From June 2006-February 2009 she was president of the National Cancer Institute of Canada. She has served on the Board of the American Society of Clinical Oncology, the Canadian Cancer Society, the Ontario Cancer Research Institute, the Canadian Institutes of Health Research Institute of Cancer Research is a member of the Scientific Audit Committee of the European Organization for Research and Treatment of Cancer. In 2008 she became co-Chair of the Canadian Cancer Research Alliance and Chair of the Research Action Group of the Canadian Partnership Against Cancer.
Dr. Iglesias was born and raised in Montevideo, Uruguay, where he graduated from Medical School in 1986. Prior to his graduation, he spent time in 1981-2 as Visiting Scientist at the Weizmann Institute of Science (Rehovot, Israel), where he worked on the immunology of lectins (plant agglutinins) with Prof. Nathan Sharon. In 1983-4 he spent a year as a fellow at Duke University Medical Center (Durham, NC), with Prof. Hillel Koren, using lectins to isolate and characterize Natural Killer (NK) cells, a prime natural defense against tumors.
After graduation from Medical School in 1986, he spent 2 years attending Oncology clinics, and in private Oncology and Hematology practice. In 1988 Dr. Iglesias came to Canada, after being awarded a post-Doctoral fellowship from the University of Toronto, where he worked with Prof. Alexander Marks of the Charles H. Best Institute and at Prof. Armand Keating’s labs at Toronto Hospital, testing the ability of NK cells from patients with Chronic Myelogenous Leukemia (CML) to eliminate malignant cells from their own bone marrow.
In 1991, Dr.Iglesias joined the Pharmaceutical Industry. He was Research Scientist at Glaxo Canada, later moving to become Associate Director of Oncology Clinical Research at Adria Laboratories of Canada. In November 1994, Dr. Iglesias joined Eli Lilly Canada as Associate Director of Clinical Research. In June 2002, he was transferred to Sydney, in the role of Oncology Medical Advisor for Eli Lilly’s Australian and Asian Operations, covering the Asia-Pacific region.
In November 2004, Dr. Iglesias returned to Canada to join AMGEN Canada as Oncology Medical Director, a position he occupied until September 2006. In such role, he was responsible for the AMGEN Oncology Clinical Trials Program in Canada.
In September 2006, Dr. Iglesias accepted the position of Vice President, Global Clinical Development, with Abraxis Oncology (now Abraxis Bioscience) and in May 2008, he became Chief Medical Officer of Abraxis Bioscience. In this global role, based in Toronto, Dr. Iglesias is responsible for the worldwide clinical development of Abraxane and other Abraxis Bioscience pipeline molecules.
Dr. Iglesias is author or co-author of more than 30 publications in the area of Oncology. For a period of 5 years, Dr. Iglesias has also served as peer-reviewer for the Canadian Institutes of Health Research (Medical Research Council of Canada) within the University-Industry Programme
BSc, MSc, MD, FRCP(C)
Natasha Leighl obtained her medical degree in 1994 from the University of Toronto, Toronto, Ontario and obtained a master's degree in Clinical Epidemiology in 2001 from the University of Newcastle, Australia. She is a Medical Oncologist at the Princess Margaret Hospital, and an Assistant Professor in the Department of Medicine at the University of Toronto. Her main interests lie in the management of lung and breast cancers, and she is involved in clinical studies of novel agents for cancer therapy. She is a member of the Lung Disease Site Group Executive and Co-Chair of the Working Group on Economic Analyses of the National Cancer Institute of Canada Clinical Trials Group. She also serves on several committees including the International Association for the Study of Lung Cancer Communications Committee, and currently chairs the Lung Cancer Canada Medical Advisory Committee as well as serving on the Board of Directors.
M.D., M.Sc., F.R.C.P(C)
Mark Levine is Chair and Professor in the Department of Oncology with a cross-appointment in Clinical Epidemiology & Biostatistics, at McMaster University, Hamilton, Ontario, Canada. He holds the Buffett Taylor Chair in Breast Cancer Research at McMaster University. He is a past recipient of the O. Harold Warwick Prize (1999) from the National Cancer Institute of Canada. Dr. Levine received his medical degree from McGill University, Montreal, Quebec, Canada, and completed his residency in internal medicine at McMaster University. He completed his training in hematology and oncology at Duke University Medical Centre, Durham, North Carolina, USA. In addition, Dr. Levine received a master’s degree in clinical epidemiology and biostatistics from McMaster University.
In 1982, Dr. Levine became a member of both the Faculty of Health Sciences at McMaster University, and a medical oncologist at the Hamilton Regional Cancer Centre (now known as the Juravinski Cancer Centre - Hamilton Health Sciences). He was CEO of the Cancer Centre between 1992 and 1999. Over the past 25 years he has been an active researcher in clinical trials and health services research. His focus is in the areas of breast cancer and venous thromboembolism. A number of the trials he has conducted have impacted on health care in both Canada and internationally. He helped establish the Ontario Clinical Oncology Group (OCOG) in 1982. Dr. Levine has over 220 publications in peer-reviewed journals and has brought much research funding to McMaster. He is Director of the Clinical Trials Methodology Group (CTMG) of the Henderson Research Centre. He was Chairman of Health Canada’s Steering Committee on Clinical Practice Guidelines for the Care and Treatment of Breast Cancer. Dr. Levine is currently an Associate Editor for the Journal of Clinical Oncology.
Dr. Ralph Meyer received his medical degree from McMaster University in Hamilton, Ontario in 1978. He completed a rotating internship at Ottawa General Hospital and residency training in Internal Medicine (1982) and Hematology (1984) at McMaster University. He joined the Department of Medicine, McMaster University in 1984 where his academic interests included clinical trials and implications for health policy in the hematologic malignancies. Dr. Meyer was Professor in the Department of Medicine, Associate Member in the Department of Pathology and Molecular Medicine and Division Director of Hematology (2000 – 2006) at McMaster University, and Head of Hematology–Oncology at the Juravinski Cancer Centre. He previously chaired the Hematology Site Committee of the NCIC Clinical Trials Group and the Hematology Disease Site Group, Cancer Care Ontario Practice Guidelines Initiative, and was a co-editor in the Malignant Hematology Group of the Cochrane Collaboration. Dr. Meyer has previously sat on the editorial boards of Cancer Treatment Reviews and the Journal of Clinical Oncology.
In April 2006, Dr. Meyer joined the NCIC Clinical Trials Group as Director Designate and in 2007 became the Group’s Director. Currently, Dr. Meyer is the Edith Eisenhauer Chair in Clinical Cancer Research, Professor in the Departments of Oncology, Medicine and Community Health and Epidemiology at Queen’s University, Kingston, Ontario, and Hematologist at the Kingston General Hospital and Cancer Centre of Southeastern Ontario.
Dr. Nicole Mittmann holds a faculty position as an Assistant Professor at the University of Toronto in the Department of Pharmacology. She is also a Scientist at Sunnybrook Health Sciences Centre and a member of the Department of Medicine. Dr. Mittmann is the Executive Director at Health Outcomes and Pharmacoeconomics (HOPE) Research Centre.
In her capacity at the HOPE Research Centre, Dr. Mittmann is responsible for designing, managing and executing health economics and clinical outcomes research projects from the government, hospital and pharmaceutical industry perspectives.
Dr. Mittmann has conducted and collaborated on research projects in the areas of meta-analysis, economic evaluations, outcomes research and utility assessments. Her research methodologies include the examination of large databases, economic methodologies and decision analysis. Her clinical areas of interest include oncology, cardiology, trauma, infectious disease and health policy.
Dr. Mittmann is currently the co-chair of the Working Group on Economic Analysis at the NCIC Clinical Trials Group. Responsibilities include embedding economic parameters in clinical trials, economic evaluations and guideline development. Through the NCIC Clinical Trials Group and the Canadian Agency for Drugs and Technologies in Health (CADTH), Dr. Mittmann was the co-principal investigator for the adaptation of economic guidelines for oncology products. This work provides national guidelines for the conduct of economic analysis for oncology products.
Dr. Mittmann is also a health innovator in residence at the Richard Ivey Business School at the University of Western Ontario. Dr. Mittmann has received funding as either a principal investigator or as a co-investigator from Canadian Institutes of Health Research (CIHR), Canadian Partnership Against Cancer, National Cancer Institute of Canada (NCIC), Neurotrauma Foundation, Heart and Stroke Foundation, Canadian Dermatology Foundation, Ontario HIV Treatment Network (OHTN), Canadian Stroke Network and the Physician Services Incorporated Foundation.
Wendy Parulekar is a graduate of the University of Ottawa Medical School where she also completed residency training in Internal Medicine and Medical Oncology (1996). This was followed by a fellowship in Clinical Pharmacology at the Toronto Sunnybrook Regional Cancer Centre. Since 1999, she has held a joint clinical/research position at Queen’s University. Within the NCIC Clinical Trials Group, she acts as Physician Coordinator for national and international studies in carcinoma of the breast, head and neck and genitourinary systems and is Chair of the Education Committee. In addition to her involvement in national and international scientific advisory committees, she is an active participant in the SPIRIT initiative whose goal is to define standard protocol items for randomized trials and is an associate editor for the journal Clinical Trials. In 2011, she was named a Fellow of the Society for Clinical Trials.
Her academic interests include the methodology of efficient clinical trial design and conduct from a non-statistician’s perspective and the art and science of mentoring in academic medicine.
Dr. Kathleen Pritchard’s research interests include clinical trials and translational approaches in the areas of adjuvant therapy, hormonal therapy, chemotherapy and optimal locoregional therapy for breast cancer. From 1994-2008, Dr. Pritchard served as Chair of the NCIC Clinical Trials Group Trials Breast Cancer Site Committee.
In 2005, Dr. Pritchard was awarded the O. Harold Warwick Prize for Cancer Control in Canada by the Canadian Cancer Society and the former National Cancer Institute of Canada for her work in clinical and translational trials in breast cancer. She is currently the Clinical Co-Chair of the Early Breast Cancer Trialists Collaborative Group (EBCTCG) Oxford Overview.
Dr. Pritchard is a Professor of Medicine at the University of Toronto, with cross-appointments in the Departments of Health Policy, Management and Evaluation and Public Health Sciences. She is Clinical Director of the Ontario Clinical Oncology Group and Senior Scientist at the Sunnybrook Odette Regional Cancer Centre at Sunnybrook Health Sciences Centre in Toronto.
BSc, MSc, PhD
After receiving a Master's Degree in Virology at the University of Quebec, Dr. Richardson received a PhD in Epidemiology & Biostatistics at McGill University, where she studied the natural history of human papillomavirus infections and cervical neoplasia. She completed her postdoctoral fellowship with Dr. Kristan Aronson (CCE Div.) in 2004, working on several projects devoted to assessing the relationship between exposure to suspected carcinogens (both environmental and occupational) and the risk of certain cancers, including breast and lung cancer. In 2004, she accepted a position as Assistant Professor in the Department of Community Health & Epidemiology and joined the NCIC CTG where she is a project coordinator for clinical trials designed to evaluate the role of selected agents in chemoprevention.
BSc, FRCP(C), MD, MSc
Dr. Ringash is an associate professor of Radiation Oncology at the University of Toronto, and a staff radiation oncologist at the Princess Margaret Hospital. She is cross appointed to the Department of Health Policy, Management and Evaluation at the University of Toronto. She previously served as Associate Programme Director for the graduate programme in Clinical Epidemiology.
Dr. Ringash obtained her BSc in Chemistry at McMaster University in 1990, and went on to obtain her MD in 1993. She trained in Radiation Oncology at McMaster University and the Hamilton Regional Cancer Centre, where she was Chief Resident from 1996-97. After obtaining her FRCP(C) in 1997, she was a clinical fellow in radiation oncology at the Princess Margaret Hospital, and simultaneously completed her MSc in Clinical Epidemiology at the University of Toronto in 1999. In 2010/11, she completed a 12 month sabbatical, which involved visits to 43 countries.
Dr. Ringash is currently co-Chair of the Quality of Life committee at the National Cancer Institute of Canada – Clinical Trials Group. Her research interests include the quality of life of cancer patients, clinical decision making, and the treatment of head and neck and GI malignancies. She has a special interest in upper GI malignancies, including esophagus and stomach cancers.
MD, FCP (SA), FRCP(C), PhD
Dr. Seymour completed training in Internal Medicine, Clinical Haematology & Medical Oncology and went on to complete her PhD, focusing on correlative studies and breast cancer. She took the position of Director of Medical Oncology at the Newfoundland Cancer Treatment and Research Foundation. In 1996 she took up her current position as co-Director of the Investigational New Drug Program at the NCIC CTG, where her primary interests are in early drug development, novel inhibitors of signaling and the cell cycle, translational and pharmaco-dynamic studies in early clinical trials and clinical research in lung cancer. She also holds the position of Professor and Medical Oncologist in the Department of Oncology.
Dr. Shepherd is a Professor in the Department of Pathology & Molecular Medicine. She completed her medical school training at McGill and spent three years in England where her interest in hematology developed. She completed her training as a Hematopathologist at the University of Ottawa and came to Kingston in 1987. Dr. Shepherd is currently the Director of the Transfusion Medicine Service & Immunology at Kingston General Hospital. Since 1989, Dr. Shepherd has worked with the NCIC CTG as a Physician Coordinator. Her focus has been in Haematology and Breast Cancer as well as the development of the National Tumor/Tissue Repositiory associated with the CTG and correlative studies in clinical trials.
Lillian Siu is a staff Medical Oncologist at Princess Margaret Hospital since 1998, and is a Professor at the University of Toronto. She is the Director of the Phase I Program and Co-Director of the Robert and Maggie Bras and Family Drug Development Program at Princess Margaret Hospital. Dr. Siu’s major research focus is in the area of new anticancer drug development, particularly with respect to phase I trials and head and neck malignancies. In 2009, she has been awarded a Cancer Care Ontario Chair in Experimental Therapeutics. In 2010, Dr. Siu was awarded by the US NCI the Michaele C.Christian Award in Oncology Drug Development. In addition, she is the principal investigator of the Princess Margaret Hospital Phase I Consortium, supported by a grant from the United States National Cancer Institute. Dr. Siu was the Chair for 2010 ASCO Grants Selection Committee, and is Co-Chair of the 2012 AACR Annual Meeting Program Committee. Dr. Siu has a strong interest in clinical trial methodology and has been one of the course directors of the ECCO/ASCO/AACR workshop in Flims, Switzerland. Dr. Siu has published over 120 peer-reviewed manuscripts and serves on the editorial board of Journal of Clinical Oncology, Cancer Discovery, European Journal of Cancer and Investigational New Drugs.
Dr. Squire joined the NCIC CTG in June 2008 as Director, Translational Laboratory Research. His responsibilities within this role include leadership in facilitating the determination of strategic directions in translational research, engagement of basic and translational laboratory-based researchers from across Canada with NCIC CTG activities, and facilitation of these research activities at the Disease Site Committee level. Before coming to the NCIC CTG, Dr. Squire was the J. C. Boileau Grant Chair in Oncologic Pathology at the University of Toronto and a Senior Scientist in the Division of Applied Molecular Oncology at the Ontario Cancer Institute. Dr. Squire received his Bachelor of Science and Master’s degrees at the Queen Mary College, University of London. He completed his PhD in Medical Biophysics at the University of Toronto.
Dr. Tsao is a Professor of Laboratory Medicine and Pathobiology at the University of Toronto, the M. Qasim Choksi Chair of Lung Cancer Translational Research Program, consultant thoracic pathologist and Senior Scientist at Princess Margaret Hospital/Ontario Cancer Institute. He is the co-Chair of the Correlative Science and Tumor Biology Committee of the National Cancer Institute of Canada Clinical Trials Group (NCIC CTG), Associate Editor of the Journal of Thoracic Oncology, Editorial Board Member of the Journal of Clinical Oncology, and members of the International Association for Study of Lung Cancer (IASLC) Committees in Pathology and in Staging (Biology Factors). Together with Dr. Stephen Lam, he co-leads the Pan-Canadian Lung Cancer Early Detection Study supported by the Terry Fox Research Institute and the Canadian Partnership Against Cancer. He is also Director of The Terry Fox Foundation Strategic Health Research Training Program in Molecular Pathology of Cancer at CIHR www.molecularpathology.ca
Dr. Tu is a Senior Biostatistician in the NCIC CTG with appointments in both the Departments of Community Health & Epidemiology, and Mathematics & Statistics. He came to Queen's in 1996 from the Therapeutic Products Directorate of Health Canada. His primary responsibilities are the design, management and analysis of the cancer clinical trials. He is also interested in the methodological research on the development and evaluation of statistical procedures for the design and analysis of cancer clinical trials and maintains an interest in the general mathematical theory of statistics.
Dr. Norman Viner is Chief of the Clinical Trials Division, Centre for Evaluation of Radiopharmaceuticals and Biotherapeutics (CERB), Biologic and Genetic Therapies Directorate (BGTD), Health Canada.
He has been managing the team of reviewers who are responsible for reviewing the clinical aspects of the applications made to the Centre since 2004. This includes the applications involving Radiopharmaceuticals, Biotherapeutic Products, Vaccines and Gene Therapies. These reviews utilize the principles of risk benefit analysis in applying the Canadian Food and Drug Regulations to the clinical trial applications which fall under the jurisdiction of this directorate.
He graduated from the University of Ottawa Medical School in 1981 and was in full time general practice in the Ottawa area for over 15 years. He remains on active staff at the Queensway Carleton Hospital in Ottawa and continues to practice Geriatric Medicine as a part-time hospitalist.
Prior to joining the Public Service, he conceived a potential smoking cessation therapy including the running of a pilot study at McMaster University, which involved the design, manufacturing and use of a prototype pharmaceutical product. He published several patents and a clinical research paper related to these efforts which lead to his joining Health Canada in1999.
Melanie Walker is a doctoral student at Queen’s University in Cancer Epidemiology where she also completed her Masters of Science in Community Health and Epidemiology in 2002. Melanie joined the NCIC Clinical Trials Group in 2001 as a Study Coordinator for a radiotherapy trial in head and neck cancer and for an international lung cancer therapy trial. Melanie was appointed as Senior Manager to the Ethics and Regulatory office in 2003 where she was responsible for establishing policies and procedures to ensure the group’s compliance with all national and international guidelines and regulations pertaining to the conduct of clinical trials in human subjects. She was also responsible for the management of informed consent review for all trials and developed and oversaw an internal safety desk for the review of adverse events. Her research interests include chemoprevention, molecular epidemiology, risk factors for cancer, clinical trial design and research ethics.
Dr. Scott Laurie received his MD from the University of Ottawa in 1994, and is certified in Internal Medicine and Medical Oncology. He completed a fellowship in Thoracic Oncology at the Memorial Sloan-Kettering Cancer Center in New York in 2000, and subsequently joined on staff at the Ottawa Hospital Cancer Centre. He is an Associate Professor at the University of Ottawa. His research interests are thoracic malignancies, salivary gland malignancies, and investigational new drugs.
Dr. Bedard is an Assistant Professor of Medicine at the University of Toronto. He is a Staff Medical Oncologist in the Division of Medical Oncology and the Fellowship Director for the Robert & Maggie Bras and Family New Drug Development Program at the Princess Margaret Cancer Centre. He received his medical degree from the University of Toronto where he was awarded the Cody Academic Silver Medal. He completed his Internal Medicine and Medical Oncology specialty training at the University of Toronto. He received additional training in clinical and translational research at the Breast International Group (BIG). He was recognized with a 2012 Career Development Award by the Conquer Cancer Foundation of the American Society of Clinical Oncology. His clinical practice includes the treatment of patients with breast and testicular cancers. His research involves early phase clinical trials and the personalization of cancer treatment based upon the results of testing for DNA mutations within tumor cells.
Susan F. Dent
BSc, MD, FRCP(C)
Dr. Dent is a Medical Oncologist at The Ottawa Hospital Cancer Centre and Associate Professor in the Department of Medicine at the University of Ottawa. She obtained her MD at McMaster University and completed her postgraduate training in Internal Medicine at the University of Ottawa. She continued her training in Medical Oncology in Ottawa, followed by a fellowship year in Clinical Research with the National Cancer Institute of Canada Clinical Trials Group. Presently, Dr. Dent is Vice Chair of the Patient Quality & Safety Committee, is a member of Cancer Care Ontario Breast Disease Site Group Practice Guidelines Committee, IND working group for the Breast Cancer Disease Site Committee of the National Cancer Institute for Canada Clinical Trials Group and Grant Review Panel for the Canadian Breast Cancer Foundation and the Canadian Institute of Health Research. She is the founder of the Canadian Cardiac Oncology Network, an organization dedicated to improving our understanding of how cancer treatments impact cardiovascular health with the ultimate goal of preventing cardiotoxicity. Her areas of interest include breast cancer treatment toxicities and cardiotoxicity.
Dr. Fei-Fei Liu is the Chief of the Radiation Medicine Program and Head of the Department of Radiation Oncology at the Princess Margaret Cancer Center, and also the Professor and Chair of the Department of Radiation Oncology at the University of Toronto. She is also a Senior Scientist at the Ontario Cancer Institute, and holds the University of Toronto/Princess Margaret Cancer Center Dr. Mariano Elia Endowed Chair in Head & Neck Cancer Oncology. Dr. Liu’s research program is focused on investigating and developing novel molecular therapeutic strategies for human malignancies, delivered in conjunction with radiation therapy, along with investigating molecular aberrancies for several human cancers including breast, cervix, and head/neck cancers. Dr. Liu has >130 peer-reviewed publications on these topics, and has filed three patents. She currently holds peer-reviewed research funding from agencies including the Canadian Institutes of Health Research (CIHR), the Canadian Cancer Society Research Institute (CCSRI), and the Ontario Institute for Cancer Research (OICR). She is also the Director of a $1.9M CIHR/Terry Fox Foundation Research Training Initiative, entitled “Excellence in Radiation Research for the 21st Century (EIRR21)”, with the objective to train the next generation of trans-disciplinary scientists in Radiation Medicine.
Candice obtained her degree in Cell Biology and Genetics at the University of British Columbia, in Vancouver, Canada, and has worked in federal regulation since 1999. Candice began her career in the Public Service in Vancouver, BC with the Canadian Food Inspection Agency as a food microbiologist, prior to joining Health Canada in 2005, where she worked in the Medical Device, Drug Investigation, and Good Clinical Practices programmes as an inspector in the Western Region. In 2009, Candice took a position with the Inspectorate’s headquarters in Ottawa, shortly afterward assuming the position of Manager of the national Good Clinical Practices Compliance Program. Here, her role is to lead the delivery of Canada’s national inspection, compliance verification, and investigation program for clinical trials of drugs for human use.
Steve Atiyeh is a seasoned professional with close to 25 years of experience in the biopharmaceutical industry. He has been at Celgene Inc. and its wholly owned subsidiary Abraxis Bioscience since 2006 as Medical Liaison Manager. Previously Steve worked in medical and other capacities at Roche, Lilly and Lederle/Wyeth, in Canada & overseas, involved in the clinical study and the accessibility of molecules to treat a wide range of solid tumors as well as hematological diseases. A graduate from the University of LaVerne, California, Steve is an active member of ASCO and IASLC, and has recently co-founded the official Montreal fanclub of European soccer giants Bayern Munich
MB ChB, MRCP, FRCPath
Dr. Annette Hay is a Hematologist and clinician scientist within the Department of Medicine, cross appointed to the Department of Oncology, and a Senior Investigator with the NCIC Clinical Trials Group. Having completed medical and hematology training in Scotland, Dr. Hay undertook 2 ½ years of fellowship with the NCIC CTG, transitioning to a Senior Investigator position in 2014. In this role her responsibilities include development and conduct of clinical trials for patients with hematological malignancies, economic evaluations of cancer interventions, and improving opportunities for adolescents and young adults with cancer to participate in clinical research. Interests also include exploration of more efficient means to conduct clinical trials, whilst upholding patient privacy and safety. [In 2012 she was awarded the prestigious John H. Crookston Award from the Canadian Hematology Society and in 2014 was the inaugural recipient of the NCIC Clinical Trials Group Dr. Ralph Meyer Phase III Young Investigator Award.]